BioSpace News Archive

BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).

According to a new study on the long-term effects of email “incivility” in the workplace, receiving negative or stressful work emails has a ripple effect on both one’s professional and personal life, even going so far as to compound your partner’s own stress levels at home and at work.

Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.

Panelists discuss successes and challenges of military surgical care and how an integrated military-civilian trauma system can help save lives

Ironwood Pharmaceuticals, Inc. announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 6, 2018.

Weight Watchers International, Inc. (NYSE: WTW) will release its results for the second quarter 2018 after the NYSE closes on Monday, August 6, 2018.

The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock on July 23, 2018.

Global Cord Blood Corporation announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission.

Windtree Therapeutics today announced that it has successfully completed design verification of its new proprietary aerosol delivery system (ADS) for AEROSURF®.

Celgene today announced results from a phase III, randomized, double-blind, international clinical study (AUGMENT). REVLIMID® (lenalidomide) plus rituximab (R2) achieved a highly statistically significant improvement in the primary endpoint of progression-free survival (PFS), compared to rituximab plus placebo, in the final PFS analysis.